Pharma & Healthcare
Global Central Nervous System (CNS) Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 569611
- Pages: 116
- Figures: 118
- Views: 8
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Central Nervous System (CNS) Therapeutics market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
UCB Pharma
Viatris
Johnson and Johnson
Eli Lilly
Biogen
Roche
Merck & Co Inc
Takeda
Novartis
Teva
Segment by Type
Neurovascular Diseases
CNS Trauma
Neurodegenerative Diseases
Other
Segment by Application
Hospital
Online
Other
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Central Nervous System (CNS) Therapeutics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Central Nervous System (CNS) Therapeutics market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
UCB Pharma
Viatris
Johnson and Johnson
Eli Lilly
Biogen
Roche
Merck & Co Inc
Takeda
Novartis
Teva
Segment by Type
Neurovascular Diseases
CNS Trauma
Neurodegenerative Diseases
Other
Segment by Application
Hospital
Online
Other
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Central Nervous System (CNS) Therapeutics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Central Nervous System (CNS) Therapeutics: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Central Nervous System (CNS) Therapeutics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Neurovascular Diseases
1.2.3 CNS Trauma
1.2.4 Neurodegenerative Diseases
1.2.5 Other
1.3 Market Segmentation by Application
1.3.1 Global Central Nervous System (CNS) Therapeutics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Online
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Central Nervous System (CNS) Therapeutics Revenue Estimates and Forecasts 2020-2031
2.2 Global Central Nervous System (CNS) Therapeutics Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Central Nervous System (CNS) Therapeutics Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Central Nervous System (CNS) Therapeutics Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Neurovascular Diseases Market Size by Players
3.3.2 CNS Trauma Market Size by Players
3.3.3 Neurodegenerative Diseases Market Size by Players
3.3.4 Other Market Size by Players
3.4 Global Central Nervous System (CNS) Therapeutics Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Central Nervous System (CNS) Therapeutics Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Central Nervous System (CNS) Therapeutics Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Central Nervous System (CNS) Therapeutics Market Size by Type (2020-2031)
6.4 North America Central Nervous System (CNS) Therapeutics Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Central Nervous System (CNS) Therapeutics Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Central Nervous System (CNS) Therapeutics Market Size by Type (2020-2031)
7.4 Europe Central Nervous System (CNS) Therapeutics Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Central Nervous System (CNS) Therapeutics Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size by Type (2020-2031)
8.4 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Central Nervous System (CNS) Therapeutics Market Size by Type (2020-2031)
9.4 Central and South America Central Nervous System (CNS) Therapeutics Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Central Nervous System (CNS) Therapeutics Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Central Nervous System (CNS) Therapeutics Market Size by Type (2020-2031)
10.4 Middle East and Africa Central Nervous System (CNS) Therapeutics Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Central Nervous System (CNS) Therapeutics Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 UCB Pharma
11.1.1 UCB Pharma Corporation Information
11.1.2 UCB Pharma Business Overview
11.1.3 UCB Pharma Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.1.4 UCB Pharma Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.1.5 UCB Pharma Central Nervous System (CNS) Therapeutics Revenue by Product in 2024
11.1.6 UCB Pharma Central Nervous System (CNS) Therapeutics Revenue by Application in 2024
11.1.7 UCB Pharma Central Nervous System (CNS) Therapeutics Revenue by Geographic Area in 2024
11.1.8 UCB Pharma Central Nervous System (CNS) Therapeutics SWOT Analysis
11.1.9 UCB Pharma Recent Developments
11.2 Viatris
11.2.1 Viatris Corporation Information
11.2.2 Viatris Business Overview
11.2.3 Viatris Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.2.4 Viatris Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.2.5 Viatris Central Nervous System (CNS) Therapeutics Revenue by Product in 2024
11.2.6 Viatris Central Nervous System (CNS) Therapeutics Revenue by Application in 2024
11.2.7 Viatris Central Nervous System (CNS) Therapeutics Revenue by Geographic Area in 2024
11.2.8 Viatris Central Nervous System (CNS) Therapeutics SWOT Analysis
11.2.9 Viatris Recent Developments
11.3 Johnson and Johnson
11.3.1 Johnson and Johnson Corporation Information
11.3.2 Johnson and Johnson Business Overview
11.3.3 Johnson and Johnson Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.3.4 Johnson and Johnson Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.3.5 Johnson and Johnson Central Nervous System (CNS) Therapeutics Revenue by Product in 2024
11.3.6 Johnson and Johnson Central Nervous System (CNS) Therapeutics Revenue by Application in 2024
11.3.7 Johnson and Johnson Central Nervous System (CNS) Therapeutics Revenue by Geographic Area in 2024
11.3.8 Johnson and Johnson Central Nervous System (CNS) Therapeutics SWOT Analysis
11.3.9 Johnson and Johnson Recent Developments
11.4 Eli Lilly
11.4.1 Eli Lilly Corporation Information
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.4.4 Eli Lilly Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.4.5 Eli Lilly Central Nervous System (CNS) Therapeutics Revenue by Product in 2024
11.4.6 Eli Lilly Central Nervous System (CNS) Therapeutics Revenue by Application in 2024
11.4.7 Eli Lilly Central Nervous System (CNS) Therapeutics Revenue by Geographic Area in 2024
11.4.8 Eli Lilly Central Nervous System (CNS) Therapeutics SWOT Analysis
11.4.9 Eli Lilly Recent Developments
11.5 Biogen
11.5.1 Biogen Corporation Information
11.5.2 Biogen Business Overview
11.5.3 Biogen Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.5.4 Biogen Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.5.5 Biogen Central Nervous System (CNS) Therapeutics Revenue by Product in 2024
11.5.6 Biogen Central Nervous System (CNS) Therapeutics Revenue by Application in 2024
11.5.7 Biogen Central Nervous System (CNS) Therapeutics Revenue by Geographic Area in 2024
11.5.8 Biogen Central Nervous System (CNS) Therapeutics SWOT Analysis
11.5.9 Biogen Recent Developments
11.6 Roche
11.6.1 Roche Corporation Information
11.6.2 Roche Business Overview
11.6.3 Roche Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.6.4 Roche Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.6.5 Roche Recent Developments
11.7 Merck & Co Inc
11.7.1 Merck & Co Inc Corporation Information
11.7.2 Merck & Co Inc Business Overview
11.7.3 Merck & Co Inc Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.7.4 Merck & Co Inc Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.7.5 Merck & Co Inc Recent Developments
11.8 Takeda
11.8.1 Takeda Corporation Information
11.8.2 Takeda Business Overview
11.8.3 Takeda Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.8.4 Takeda Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.8.5 Takeda Recent Developments
11.9 Novartis
11.9.1 Novartis Corporation Information
11.9.2 Novartis Business Overview
11.9.3 Novartis Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.9.4 Novartis Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.9.5 Novartis Recent Developments
11.10 Teva
11.10.1 Teva Corporation Information
11.10.2 Teva Business Overview
11.10.3 Teva Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.10.4 Teva Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
12 Central Nervous System (CNS) TherapeuticsIndustry Chain Analysis
12.1 Central Nervous System (CNS) Therapeutics Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Central Nervous System (CNS) Therapeutics Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Central Nervous System (CNS) Therapeutics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Central Nervous System (CNS) Therapeutics: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Central Nervous System (CNS) Therapeutics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Neurovascular Diseases
1.2.3 CNS Trauma
1.2.4 Neurodegenerative Diseases
1.2.5 Other
1.3 Market Segmentation by Application
1.3.1 Global Central Nervous System (CNS) Therapeutics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Online
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Central Nervous System (CNS) Therapeutics Revenue Estimates and Forecasts 2020-2031
2.2 Global Central Nervous System (CNS) Therapeutics Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Central Nervous System (CNS) Therapeutics Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Central Nervous System (CNS) Therapeutics Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Neurovascular Diseases Market Size by Players
3.3.2 CNS Trauma Market Size by Players
3.3.3 Neurodegenerative Diseases Market Size by Players
3.3.4 Other Market Size by Players
3.4 Global Central Nervous System (CNS) Therapeutics Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Central Nervous System (CNS) Therapeutics Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Central Nervous System (CNS) Therapeutics Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Central Nervous System (CNS) Therapeutics Market Size by Type (2020-2031)
6.4 North America Central Nervous System (CNS) Therapeutics Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Central Nervous System (CNS) Therapeutics Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Central Nervous System (CNS) Therapeutics Market Size by Type (2020-2031)
7.4 Europe Central Nervous System (CNS) Therapeutics Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Central Nervous System (CNS) Therapeutics Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size by Type (2020-2031)
8.4 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Central Nervous System (CNS) Therapeutics Market Size by Type (2020-2031)
9.4 Central and South America Central Nervous System (CNS) Therapeutics Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Central Nervous System (CNS) Therapeutics Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Central Nervous System (CNS) Therapeutics Market Size by Type (2020-2031)
10.4 Middle East and Africa Central Nervous System (CNS) Therapeutics Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Central Nervous System (CNS) Therapeutics Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 UCB Pharma
11.1.1 UCB Pharma Corporation Information
11.1.2 UCB Pharma Business Overview
11.1.3 UCB Pharma Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.1.4 UCB Pharma Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.1.5 UCB Pharma Central Nervous System (CNS) Therapeutics Revenue by Product in 2024
11.1.6 UCB Pharma Central Nervous System (CNS) Therapeutics Revenue by Application in 2024
11.1.7 UCB Pharma Central Nervous System (CNS) Therapeutics Revenue by Geographic Area in 2024
11.1.8 UCB Pharma Central Nervous System (CNS) Therapeutics SWOT Analysis
11.1.9 UCB Pharma Recent Developments
11.2 Viatris
11.2.1 Viatris Corporation Information
11.2.2 Viatris Business Overview
11.2.3 Viatris Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.2.4 Viatris Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.2.5 Viatris Central Nervous System (CNS) Therapeutics Revenue by Product in 2024
11.2.6 Viatris Central Nervous System (CNS) Therapeutics Revenue by Application in 2024
11.2.7 Viatris Central Nervous System (CNS) Therapeutics Revenue by Geographic Area in 2024
11.2.8 Viatris Central Nervous System (CNS) Therapeutics SWOT Analysis
11.2.9 Viatris Recent Developments
11.3 Johnson and Johnson
11.3.1 Johnson and Johnson Corporation Information
11.3.2 Johnson and Johnson Business Overview
11.3.3 Johnson and Johnson Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.3.4 Johnson and Johnson Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.3.5 Johnson and Johnson Central Nervous System (CNS) Therapeutics Revenue by Product in 2024
11.3.6 Johnson and Johnson Central Nervous System (CNS) Therapeutics Revenue by Application in 2024
11.3.7 Johnson and Johnson Central Nervous System (CNS) Therapeutics Revenue by Geographic Area in 2024
11.3.8 Johnson and Johnson Central Nervous System (CNS) Therapeutics SWOT Analysis
11.3.9 Johnson and Johnson Recent Developments
11.4 Eli Lilly
11.4.1 Eli Lilly Corporation Information
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.4.4 Eli Lilly Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.4.5 Eli Lilly Central Nervous System (CNS) Therapeutics Revenue by Product in 2024
11.4.6 Eli Lilly Central Nervous System (CNS) Therapeutics Revenue by Application in 2024
11.4.7 Eli Lilly Central Nervous System (CNS) Therapeutics Revenue by Geographic Area in 2024
11.4.8 Eli Lilly Central Nervous System (CNS) Therapeutics SWOT Analysis
11.4.9 Eli Lilly Recent Developments
11.5 Biogen
11.5.1 Biogen Corporation Information
11.5.2 Biogen Business Overview
11.5.3 Biogen Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.5.4 Biogen Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.5.5 Biogen Central Nervous System (CNS) Therapeutics Revenue by Product in 2024
11.5.6 Biogen Central Nervous System (CNS) Therapeutics Revenue by Application in 2024
11.5.7 Biogen Central Nervous System (CNS) Therapeutics Revenue by Geographic Area in 2024
11.5.8 Biogen Central Nervous System (CNS) Therapeutics SWOT Analysis
11.5.9 Biogen Recent Developments
11.6 Roche
11.6.1 Roche Corporation Information
11.6.2 Roche Business Overview
11.6.3 Roche Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.6.4 Roche Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.6.5 Roche Recent Developments
11.7 Merck & Co Inc
11.7.1 Merck & Co Inc Corporation Information
11.7.2 Merck & Co Inc Business Overview
11.7.3 Merck & Co Inc Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.7.4 Merck & Co Inc Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.7.5 Merck & Co Inc Recent Developments
11.8 Takeda
11.8.1 Takeda Corporation Information
11.8.2 Takeda Business Overview
11.8.3 Takeda Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.8.4 Takeda Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.8.5 Takeda Recent Developments
11.9 Novartis
11.9.1 Novartis Corporation Information
11.9.2 Novartis Business Overview
11.9.3 Novartis Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.9.4 Novartis Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.9.5 Novartis Recent Developments
11.10 Teva
11.10.1 Teva Corporation Information
11.10.2 Teva Business Overview
11.10.3 Teva Central Nervous System (CNS) Therapeutics Product Features and Attributes
11.10.4 Teva Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
12 Central Nervous System (CNS) TherapeuticsIndustry Chain Analysis
12.1 Central Nervous System (CNS) Therapeutics Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Central Nervous System (CNS) Therapeutics Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Central Nervous System (CNS) Therapeutics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Central Nervous System (CNS) Therapeutics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Central Nervous System (CNS) Therapeutics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Central Nervous System (CNS) Therapeutics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Central Nervous System (CNS) Therapeutics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Central Nervous System (CNS) Therapeutics Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Central Nervous System (CNS) Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Central Nervous System (CNS) Therapeutics by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Central Nervous System (CNS) Therapeutics as of 2024)
Table 11. Global Central Nervous System (CNS) Therapeutics Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Central Nervous System (CNS) Therapeutics Companies Headquarters
Table 13. Global Central Nervous System (CNS) Therapeutics Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Central Nervous System (CNS) Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Central Nervous System (CNS) Therapeutics Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Central Nervous System (CNS) Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Central Nervous System (CNS) Therapeutics Revenue by Application (2026-2031) & (US$ Million)
Table 21. Central Nervous System (CNS) Therapeutics High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Central Nervous System (CNS) Therapeutics Growth Accelerators and Market Barriers
Table 25. North America Central Nervous System (CNS) Therapeutics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Central Nervous System (CNS) Therapeutics Growth Accelerators and Market Barriers
Table 27. Europe Central Nervous System (CNS) Therapeutics Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Central Nervous System (CNS) Therapeutics Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Central Nervous System (CNS) Therapeutics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Central Nervous System (CNS) Therapeutics Investment Opportunities and Key Challenges
Table 31. Central and South America Central Nervous System (CNS) Therapeutics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Central Nervous System (CNS) Therapeutics Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Central Nervous System (CNS) Therapeutics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. UCB Pharma Corporation Information
Table 35. UCB Pharma Description and Major Businesses
Table 36. UCB Pharma Product Features and Attributes
Table 37. UCB Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. UCB Pharma Revenue Proportion by Product in 2024
Table 39. UCB Pharma Revenue Proportion by Application in 2024
Table 40. UCB Pharma Revenue Proportion by Geographic Area in 2024
Table 41. UCB Pharma Central Nervous System (CNS) Therapeutics SWOT Analysis
Table 42. UCB Pharma Recent Developments
Table 43. Viatris Corporation Information
Table 44. Viatris Description and Major Businesses
Table 45. Viatris Product Features and Attributes
Table 46. Viatris Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Viatris Revenue Proportion by Product in 2024
Table 48. Viatris Revenue Proportion by Application in 2024
Table 49. Viatris Revenue Proportion by Geographic Area in 2024
Table 50. Viatris Central Nervous System (CNS) Therapeutics SWOT Analysis
Table 51. Viatris Recent Developments
Table 52. Johnson and Johnson Corporation Information
Table 53. Johnson and Johnson Description and Major Businesses
Table 54. Johnson and Johnson Product Features and Attributes
Table 55. Johnson and Johnson Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Johnson and Johnson Revenue Proportion by Product in 2024
Table 57. Johnson and Johnson Revenue Proportion by Application in 2024
Table 58. Johnson and Johnson Revenue Proportion by Geographic Area in 2024
Table 59. Johnson and Johnson Central Nervous System (CNS) Therapeutics SWOT Analysis
Table 60. Johnson and Johnson Recent Developments
Table 61. Eli Lilly Corporation Information
Table 62. Eli Lilly Description and Major Businesses
Table 63. Eli Lilly Product Features and Attributes
Table 64. Eli Lilly Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Eli Lilly Revenue Proportion by Product in 2024
Table 66. Eli Lilly Revenue Proportion by Application in 2024
Table 67. Eli Lilly Revenue Proportion by Geographic Area in 2024
Table 68. Eli Lilly Central Nervous System (CNS) Therapeutics SWOT Analysis
Table 69. Eli Lilly Recent Developments
Table 70. Biogen Corporation Information
Table 71. Biogen Description and Major Businesses
Table 72. Biogen Product Features and Attributes
Table 73. Biogen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Biogen Revenue Proportion by Product in 2024
Table 75. Biogen Revenue Proportion by Application in 2024
Table 76. Biogen Revenue Proportion by Geographic Area in 2024
Table 77. Biogen Central Nervous System (CNS) Therapeutics SWOT Analysis
Table 78. Biogen Recent Developments
Table 79. Roche Corporation Information
Table 80. Roche Description and Major Businesses
Table 81. Roche Product Features and Attributes
Table 82. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Roche Recent Developments
Table 84. Merck & Co Inc Corporation Information
Table 85. Merck & Co Inc Description and Major Businesses
Table 86. Merck & Co Inc Product Features and Attributes
Table 87. Merck & Co Inc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Merck & Co Inc Recent Developments
Table 89. Takeda Corporation Information
Table 90. Takeda Description and Major Businesses
Table 91. Takeda Product Features and Attributes
Table 92. Takeda Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Takeda Recent Developments
Table 94. Novartis Corporation Information
Table 95. Novartis Description and Major Businesses
Table 96. Novartis Product Features and Attributes
Table 97. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Novartis Recent Developments
Table 99. Teva Corporation Information
Table 100. Teva Description and Major Businesses
Table 101. Teva Product Features and Attributes
Table 102. Teva Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Teva Recent Developments
Table 104. Raw Materials Key Suppliers
Table 105. Distributors List
Table 106. Market Trends and Market Evolution
Table 107. Market Drivers and Opportunities
Table 108. Market Challenges, Risks, and Restraints
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Central Nervous System (CNS) Therapeutics Product Picture
Figure 2. Global Central Nervous System (CNS) Therapeutics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Neurovascular Diseases Product Picture
Figure 4. CNS Trauma Product Picture
Figure 5. Neurodegenerative Diseases Product Picture
Figure 6. Other Product Picture
Figure 7. Global Central Nervous System (CNS) Therapeutics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hospital
Figure 9. Online
Figure 10. Other
Figure 11. Central Nervous System (CNS) Therapeutics Report Years Considered
Figure 12. Global Central Nervous System (CNS) Therapeutics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 14. Global Central Nervous System (CNS) Therapeutics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Region (2020-2031)
Figure 16. Global Central Nervous System (CNS) Therapeutics Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Neurovascular Diseases Revenue Market Share by Player in 2024
Figure 19. CNS Trauma Revenue Market Share by Player in 2024
Figure 20. Neurodegenerative Diseases Revenue Market Share by Player in 2024
Figure 21. Other Revenue Market Share by Player in 2024
Figure 22. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Type (2020-2031)
Figure 23. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Application (2020-2031)
Figure 24. North America Central Nervous System (CNS) Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 25. North America Top 5 Players Central Nervous System (CNS) Therapeutics Revenue (US$ Million) in 2024
Figure 26. North America Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Type (2020 - 2031)
Figure 27. North America Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 28. US Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 29. Canada Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 30. Mexico Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 31. Europe Central Nervous System (CNS) Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 32. Europe Top 5 Players Central Nervous System (CNS) Therapeutics Revenue (US$ Million) in 2024
Figure 33. Europe Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 34. Europe Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 35. Germany Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 36. France Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 37. U.K. Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 38. Italy Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 39. Russia Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Central Nervous System (CNS) Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Top 8 Players Central Nervous System (CNS) Therapeutics Revenue (US$ Million) in 2024
Figure 42. Asia-Pacific Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 43. Asia-Pacific Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 44. Indonesia Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 45. Japan Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 46. South Korea Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 47. Australia Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 48. India Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 49. Indonesia Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 50. Vietnam Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 51. Malaysia Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 52. Philippines Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 53. Singapore Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 54. Central and South America Central Nervous System (CNS) Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Central and South America Top 5 Players Central Nervous System (CNS) Therapeutics Revenue (US$ Million) in 2024
Figure 56. Central and South America Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 57. Central and South America Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 58. Brazil Central Nervous System (CNS) Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 59. Argentina Central Nervous System (CNS) Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 60. Middle East and Africa Central Nervous System (CNS) Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Middle East and Africa Top 5 Players Central Nervous System (CNS) Therapeutics Revenue (US$ Million) in 2024
Figure 62. South America Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 63. Middle East and Africa Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 64. GCC Countries Central Nervous System (CNS) Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 65. Israel Central Nervous System (CNS) Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 66. Egypt Central Nervous System (CNS) Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 67. South Africa Central Nervous System (CNS) Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 68. Central Nervous System (CNS) Therapeutics Industry Chain Mapping
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Table 1. Global Central Nervous System (CNS) Therapeutics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Central Nervous System (CNS) Therapeutics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Central Nervous System (CNS) Therapeutics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Central Nervous System (CNS) Therapeutics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Central Nervous System (CNS) Therapeutics Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Central Nervous System (CNS) Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Central Nervous System (CNS) Therapeutics by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Central Nervous System (CNS) Therapeutics as of 2024)
Table 11. Global Central Nervous System (CNS) Therapeutics Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Central Nervous System (CNS) Therapeutics Companies Headquarters
Table 13. Global Central Nervous System (CNS) Therapeutics Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Central Nervous System (CNS) Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Central Nervous System (CNS) Therapeutics Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Central Nervous System (CNS) Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Central Nervous System (CNS) Therapeutics Revenue by Application (2026-2031) & (US$ Million)
Table 21. Central Nervous System (CNS) Therapeutics High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Central Nervous System (CNS) Therapeutics Growth Accelerators and Market Barriers
Table 25. North America Central Nervous System (CNS) Therapeutics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Central Nervous System (CNS) Therapeutics Growth Accelerators and Market Barriers
Table 27. Europe Central Nervous System (CNS) Therapeutics Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Central Nervous System (CNS) Therapeutics Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Central Nervous System (CNS) Therapeutics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Central Nervous System (CNS) Therapeutics Investment Opportunities and Key Challenges
Table 31. Central and South America Central Nervous System (CNS) Therapeutics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Central Nervous System (CNS) Therapeutics Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Central Nervous System (CNS) Therapeutics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. UCB Pharma Corporation Information
Table 35. UCB Pharma Description and Major Businesses
Table 36. UCB Pharma Product Features and Attributes
Table 37. UCB Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. UCB Pharma Revenue Proportion by Product in 2024
Table 39. UCB Pharma Revenue Proportion by Application in 2024
Table 40. UCB Pharma Revenue Proportion by Geographic Area in 2024
Table 41. UCB Pharma Central Nervous System (CNS) Therapeutics SWOT Analysis
Table 42. UCB Pharma Recent Developments
Table 43. Viatris Corporation Information
Table 44. Viatris Description and Major Businesses
Table 45. Viatris Product Features and Attributes
Table 46. Viatris Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Viatris Revenue Proportion by Product in 2024
Table 48. Viatris Revenue Proportion by Application in 2024
Table 49. Viatris Revenue Proportion by Geographic Area in 2024
Table 50. Viatris Central Nervous System (CNS) Therapeutics SWOT Analysis
Table 51. Viatris Recent Developments
Table 52. Johnson and Johnson Corporation Information
Table 53. Johnson and Johnson Description and Major Businesses
Table 54. Johnson and Johnson Product Features and Attributes
Table 55. Johnson and Johnson Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Johnson and Johnson Revenue Proportion by Product in 2024
Table 57. Johnson and Johnson Revenue Proportion by Application in 2024
Table 58. Johnson and Johnson Revenue Proportion by Geographic Area in 2024
Table 59. Johnson and Johnson Central Nervous System (CNS) Therapeutics SWOT Analysis
Table 60. Johnson and Johnson Recent Developments
Table 61. Eli Lilly Corporation Information
Table 62. Eli Lilly Description and Major Businesses
Table 63. Eli Lilly Product Features and Attributes
Table 64. Eli Lilly Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Eli Lilly Revenue Proportion by Product in 2024
Table 66. Eli Lilly Revenue Proportion by Application in 2024
Table 67. Eli Lilly Revenue Proportion by Geographic Area in 2024
Table 68. Eli Lilly Central Nervous System (CNS) Therapeutics SWOT Analysis
Table 69. Eli Lilly Recent Developments
Table 70. Biogen Corporation Information
Table 71. Biogen Description and Major Businesses
Table 72. Biogen Product Features and Attributes
Table 73. Biogen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Biogen Revenue Proportion by Product in 2024
Table 75. Biogen Revenue Proportion by Application in 2024
Table 76. Biogen Revenue Proportion by Geographic Area in 2024
Table 77. Biogen Central Nervous System (CNS) Therapeutics SWOT Analysis
Table 78. Biogen Recent Developments
Table 79. Roche Corporation Information
Table 80. Roche Description and Major Businesses
Table 81. Roche Product Features and Attributes
Table 82. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Roche Recent Developments
Table 84. Merck & Co Inc Corporation Information
Table 85. Merck & Co Inc Description and Major Businesses
Table 86. Merck & Co Inc Product Features and Attributes
Table 87. Merck & Co Inc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Merck & Co Inc Recent Developments
Table 89. Takeda Corporation Information
Table 90. Takeda Description and Major Businesses
Table 91. Takeda Product Features and Attributes
Table 92. Takeda Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Takeda Recent Developments
Table 94. Novartis Corporation Information
Table 95. Novartis Description and Major Businesses
Table 96. Novartis Product Features and Attributes
Table 97. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Novartis Recent Developments
Table 99. Teva Corporation Information
Table 100. Teva Description and Major Businesses
Table 101. Teva Product Features and Attributes
Table 102. Teva Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Teva Recent Developments
Table 104. Raw Materials Key Suppliers
Table 105. Distributors List
Table 106. Market Trends and Market Evolution
Table 107. Market Drivers and Opportunities
Table 108. Market Challenges, Risks, and Restraints
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Central Nervous System (CNS) Therapeutics Product Picture
Figure 2. Global Central Nervous System (CNS) Therapeutics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Neurovascular Diseases Product Picture
Figure 4. CNS Trauma Product Picture
Figure 5. Neurodegenerative Diseases Product Picture
Figure 6. Other Product Picture
Figure 7. Global Central Nervous System (CNS) Therapeutics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hospital
Figure 9. Online
Figure 10. Other
Figure 11. Central Nervous System (CNS) Therapeutics Report Years Considered
Figure 12. Global Central Nervous System (CNS) Therapeutics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 14. Global Central Nervous System (CNS) Therapeutics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Region (2020-2031)
Figure 16. Global Central Nervous System (CNS) Therapeutics Revenue Market Share Ranking (2024)
Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 18. Neurovascular Diseases Revenue Market Share by Player in 2024
Figure 19. CNS Trauma Revenue Market Share by Player in 2024
Figure 20. Neurodegenerative Diseases Revenue Market Share by Player in 2024
Figure 21. Other Revenue Market Share by Player in 2024
Figure 22. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Type (2020-2031)
Figure 23. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Application (2020-2031)
Figure 24. North America Central Nervous System (CNS) Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 25. North America Top 5 Players Central Nervous System (CNS) Therapeutics Revenue (US$ Million) in 2024
Figure 26. North America Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Type (2020 - 2031)
Figure 27. North America Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 28. US Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 29. Canada Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 30. Mexico Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 31. Europe Central Nervous System (CNS) Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 32. Europe Top 5 Players Central Nervous System (CNS) Therapeutics Revenue (US$ Million) in 2024
Figure 33. Europe Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 34. Europe Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 35. Germany Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 36. France Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 37. U.K. Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 38. Italy Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 39. Russia Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Central Nervous System (CNS) Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Top 8 Players Central Nervous System (CNS) Therapeutics Revenue (US$ Million) in 2024
Figure 42. Asia-Pacific Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 43. Asia-Pacific Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 44. Indonesia Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 45. Japan Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 46. South Korea Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 47. Australia Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 48. India Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 49. Indonesia Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 50. Vietnam Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 51. Malaysia Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 52. Philippines Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 53. Singapore Central Nervous System (CNS) Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 54. Central and South America Central Nervous System (CNS) Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 55. Central and South America Top 5 Players Central Nervous System (CNS) Therapeutics Revenue (US$ Million) in 2024
Figure 56. Central and South America Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 57. Central and South America Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 58. Brazil Central Nervous System (CNS) Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 59. Argentina Central Nervous System (CNS) Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 60. Middle East and Africa Central Nervous System (CNS) Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 61. Middle East and Africa Top 5 Players Central Nervous System (CNS) Therapeutics Revenue (US$ Million) in 2024
Figure 62. South America Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 63. Middle East and Africa Central Nervous System (CNS) Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 64. GCC Countries Central Nervous System (CNS) Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 65. Israel Central Nervous System (CNS) Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 66. Egypt Central Nervous System (CNS) Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 67. South Africa Central Nervous System (CNS) Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 68. Central Nervous System (CNS) Therapeutics Industry Chain Mapping
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232